VRDN
Companies
NASDAQ
Viridian Therapeutics Inc.
Health Care
$15.00
-$4.17 (-21.75%)
Price Chart
Overview
About VRDN
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.
Market Cap
$776.7M
Volume
12.4M
Avg. Volume
13.8M
P/E Ratio
-3.30622
Dividend Yield
0.00%
Employees
103.0
Company Information
Risk & Correlation Analysis
Market Correlation
0.85
Moderate Correlation
Volatility
High (0.66)
Relative to market
Macro Factor Sensitivities
Interest Rates
Low Sensitivity
Inflation
Medium Sensitivity
GDP Growth
Low Sensitivity
Liquidity
Low Sensitivity
Commodity Prices
Low Sensitivity
Credit Quality
High Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, VRDN shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Pricing info last updated June 18, 2025 (after market close)Other info last updated April 2, 2025